Prothena (PRTA) Projected to Post Quarterly Earnings on Thursday

Prothena (NASDAQ:PRTA) is anticipated to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Prothena to post earnings of ($0.2271) per share and revenue of $9.58 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:00 PM ET.

Prothena (NASDAQ:PRTA) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. The firm had revenue of $1.01 million for the quarter, compared to analyst estimates of $0.42 million. Prothena had a negative net margin of 80.68% and a negative return on equity of 16.45%. On average, analysts expect Prothena to post $0.08 EPS for the current fiscal year and ($1.13) EPS for the next fiscal year.

Prothena Stock Up 3.3%

Prothena stock opened at $9.10 on Thursday. The stock has a market capitalization of $476.41 million, a PE ratio of -10.83, a price-to-earnings-growth ratio of 2.89 and a beta of -0.29. Prothena has a twelve month low of $7.73 and a twelve month high of $11.80. The company has a 50 day moving average of $8.78 and a 200-day moving average of $9.23.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Wall Street Zen lowered shares of Prothena from a “buy” rating to a “hold” rating in a report on Saturday, July 25th. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Prothena in a research note on Friday, July 24th. UBS Group reaffirmed a “buy” rating on shares of Prothena in a research report on Friday, July 24th. Finally, Weiss Ratings upgraded Prothena from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Insider Transactions at Prothena

In other Prothena news, major shareholder William P. Scully purchased 50,000 shares of the stock in a transaction on Friday, October 23rd. The shares were purchased at an average cost of $8.07 per share, for a total transaction of $403,500.00. Following the purchase, the insider owned 1,187,000 shares of the company’s stock, valued at approximately $9,579,090. This represents a 4.40% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders have acquired 1,017,500 shares of company stock valued at $8,654,850. 10.40% of the stock is currently owned by insiders.

Prothena Company Profile

Prothena Corporation plc (NASDAQ: PRTA) is a clinical-stage biotechnology company focused on discovering and developing novel medicines for serious neurodegenerative and rare peripheral diseases. Its research is centered on disease-causing proteins, including amyloid-beta, alpha-synuclein and transthyretin, with the goal of creating antibody-based therapies that address underlying disease mechanisms.

The company’s product pipeline has included birtamimab, an investigational antibody being developed for the treatment of AL amyloidosis, and prasinezumab, an investigational alpha-synuclein antibody being developed in collaboration with Roche for certain forms of Parkinson’s disease.